Private equity firm Bain Capital (BCSF) is paying $3.4 billion to buy a 350-year-old Japanese drugs group fighting diabetes ...

TOKYO & BOSTON--(BUSINESS WIRE)--Bain Capital, a leading global private investment firm, today announced it has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation ...

Hillenbrand and Bain Capital undertake no obligation to publicly update or revise any forward-looking statement, whether written or oral, made to reflect new information, future developments or ...

Independent company plans significant investment in innovation, both internal product development and external licensing and acquisitions, supported by Bain Capital investment Founded in 1678 ...

“Milacron is an iconic American manufacturing business with a 50-year legacy of driving innovation in plastics,” said Matt Evans, a partner at Bain Capital Special Situations in a statement.

Bain Capital, an investment firm that has spread its life sciences bets mainly across companies developing novel new medicines, is acquiring Mitsubishi Tanabe Pharma Corporation in a multi-billion ...

Keith Largay joins Bain Capital from JLL, where he spent 14 years and most recently served as co-head of its Chicago office.

Keith Largay joined Bain Capital’s real estate business as head of real estate capital markets, a spokesperson confirmed. It is a new position. Largay oversees the team’s debt and financing ...

Following rumblings of a private equity bidding war late last year, Bain Capital has emerged triumphant on its quest to obtain Japanese drugmaker Mitsubishi Tanabe Pharma. Bain is laying out 510 ...